Christopher J. Jankosky

Neurology
1430 Morton St
Jbphh, HI 96860

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1 publications

NLX-112 Randomized Phase 2A Trial: Safety, Tolerability, Anti-Dyskinetic, and Anti-Parkinsonian Efficacy.

NLX-112 Randomized Phase 2A Trial: Safety, Tolerability, Anti-Dyskinetic, and Anti-Parkinsonian Efficacy.

Journal: Movement disorders : official journal of the Movement Disorder Society
Published: December 18, 2024
Showing 1-1 of 1

Last Updated: 09/26/2026